z-logo
Premium
Superficial CD 34 positive fibroblastic tumor: report of three cases and review of the literature
Author(s) -
Batur Sebnem,
Ozcan Kerem,
Ozcan Gamze,
Tosun Ilkay,
Comunoglu Nil
Publication year - 2019
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/ijd.14357
Subject(s) - pleomorphism (cytology) , cd34 , medicine , desmin , pathology , immunohistochemistry , neoplasm , thigh , soft tissue , solitary fibrous tumor , histology , anatomy , vimentin , stem cell , biology , genetics
Superficial CD 34 positive fibroblastic tumor ( SCPFT ) is a recently recognized, unique neoplasm with distinctive histomorphological features such as high pleomorphism, low mitotic rate, and diffuse CD 34 reactivity. Hereby we present three cases of our experience with clinicopathological, morphological, and immunohistochemical characteristics. The patients were a 31‐year‐old female, 53‐year‐old female, and 33‐year‐old male. The tumors were all superficially located; left forearm, medial aspect of the left ankle, and left thigh, respectively. Histomorphologically they had expansile and focal infiltrative growth pattern consisting of highly pleomorphic spindle cells with intranuclear inclusions, yet low mitotic rate. Tumoral cells showed strong and diffuse reactivity for CD 34. One of our cases showed focal and weak reactivity for pancytokeratin. Unlike the other two tumors, one case was positive for desmin. During the clinical follow‐up, one case showed local recurrence four times. SCPFT is a newly recognized, borderline mesenchymal neoplasm of soft tissues that can show local recurrence or even rarely metastasize. To the best of our knowledge, this three case series is the first to be reported from Turkey. Our aim to report these three cases was to make contribution to the literature about this rare entity and increase awareness.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here